Role of Chymase-Dependent Angiotensin II Formation in Monocrotaline-Induced Pulmonary Hypertensive Rats

被引:0
作者
Kanta Kishi
Denan Jin
Shinji Takai
Michiko Muramatsu
Hiroshi Katayama
Hiroshi Tamai
Mizuo Miyazaki
机构
[1] Osaka Medical College,Department of Pharmacology
[2] 2-7 Daigaku-machi,Department of Pediatrics
[3] Osaka Medical College,undefined
[4] 2-7 Daigaku-machi,undefined
来源
Pediatric Research | 2006年 / 60卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Angiotensin II-forming chymase is expressed in the pulmonary arteries of the monocrotaline-induced pulmonary hypertensive rats, but its actual role is unclear. We studied chymase-dependent angiotensin II formation in the pulmonary arteries of the monocrotaline-induced pulmonary hypertensive rats and observed the effects of an angiotensin II receptor blocker on vascular remodeling. Four weeks after the administration of monocrotaline (60 mg/kg, s.q.), echocardiographic, hemodynamic, morphometric and biochemical analyses were performed. Age-matched rats were used as controls. To evaluate the effects of an angiotensin II receptor blocker, 2 wk after beginning of monocrotaline treatment, the rats were given candesartan (10 mg/kg per day) or placebo for 2 wk. In the monocrotaline-induced pulmonary hypertensive rats, the elevated systolic pulmonary arterial pressure and right ventricular hypertrophy were observed. Medial hypertrophy of lung arterioles was also observed. Chymase activity and angiotensin II concentration, but not angiotensin-converting enzyme activity, were significantly increased in the lung. In the angiotensin II receptor blocker-treated group, both systolic pulmonary arterial pressure and right ventricular hypertrophy were significantly reduced, and arteriolar hypertrophy was also prevented. Thus, angiotensin II-forming chymase may play a role in the proliferation of the medial layer in the lung arterioles of monocrotaline-induced pulmonary hypertensive rats.
引用
收藏
页码:77 / 82
页数:5
相关论文
共 160 条
[1]  
Urata H(1990)Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart J Biol Chem 265 22348-22357
[2]  
Kinoshita A(1997)Characterization of chymase from human vascular tissues Clin Chim Acta 265 13-20
[3]  
Misono KS(1993)Marked species-difference in the vascular angiotensin II-forming pathways: humans versus rodents Jpn J Pharmacol 62 207-210
[4]  
Bumpus FM(2004)Chymase as a novel target for the prevention of vascular diseases Trends Pharmacol Sci 25 518-522
[5]  
Husain A(1995)Human prochymase activation. A novel role for heparin in zymogen processing J Biol Chem 270 2218-2223
[6]  
Takai S(1984)Angiotensin I conversion by human and rat chymotryptic proteinases J Invest Dermatol 83 336-339
[7]  
Shiota N(2001)A novel vascular smooth muscle chymase is upregulated in hypertensive rats J Clin Invest 107 703-715
[8]  
Sakaguchi M(2001)Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice Proc Natl Acad Sci U S A 98 7469-7474
[9]  
Muraguchi H(2003)Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation Cardiovasc Drug Rev 21 185-198
[10]  
Matsumura E(1982)Angiotensin converting enzyme activity and evolution of pulmonary vascular disease in rats with monocrotaline pulmonary hypertension Thorax 37 88-96